About: Diabetes, glycaemic control, and risk of COVID-19 hospitalisation: population-based, prospective cohort study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Diabetes, glycaemic control, and risk of COVID-19 hospitalisation: population-based, prospective cohort study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Diabetes, glycaemic control, and risk of COVID-19 hospitalisation: population-based, prospective cohort study
Creator	David Batty, G Gale, Catharine Hamer, Mark
Source	Elsevier; Medline; PMC
abstract	OBJECTIVE: We aimed to examine the prospective association of diabetes and glycaemic control with COVID-19 hospitalisation in a large community-based cohort study. Methods and Study Design. Participants (N = 337,802, aged 56.4 ± 8.1 yr; 55.1% women) underwent biomedical assessments at baseline as part of the UK Biobank prospective cohort study. The outcome was cases of COVID-19 serious enough to warrant a hospital admission from 16-March-2020 to 26-April-2020. RESULTS: At follow up, 649 cases COVID-19 were recorded. In multivariable adjusted analyses, risk of COVID-19 was elevated in people with undiagnosed diabetes at baseline (A1C ≥ 6.5%) (risk ratio = 2.68; 95% confidence interval: 1.66, 4.33) and poorly controlled (A1C ≥ 8.6%) diagnosed diabetes (1.91;1.04, 3.52). There was a dose-dependent increase in risk of COVID-19 with increasing A1C, that persisted in multivariable adjusted models (per SD [0.9%]: 1.07; 1.03, 1.11; p[trend] < 0.001). CONCLUSION: In this large community-based sample, higher levels of A1C within the normal range was a risk factor for COVID-19. Glucose regulation may play a key role in immune responses to this infection. Undiagnosed cases of diabetes in the general community may present a particularly high risk.
has issue date	2020-08-22(xsd:dateTime)
bibo:doi	10.1016/j.metabol.2020.154344
bibo:pmid	32835758
has license	no-cc
sha1sum (hex)	de2b2144f419370d4d494879991d1e133accb3f9
schema:url	https://doi.org/10.1016/j.metabol.2020.154344
resource representing a document's title	Diabetes, glycaemic control, and risk of COVID-19 hospitalisation: population-based, prospective cohort study
has PubMed Central identifier	PMC7442562
has PubMed identifier	32835758
schema:publication	Metabolism
resource representing a document's body	covid:de2b2144f419370d4d494879991d1e133accb3f9#body_text
is schema:about of	named entity 'BASED' named entity 'glycaemic control' named entity 'cohort study' named entity 'Diabetes' named entity 'population-based' named entity 'meta-analysis' named entity 'general population' named entity 'infection' named entity 'A1C' named entity 'A1C' named entity 'prospective cohort study' named entity 'infection' named entity 'COVID-19' named entity 'COVID-19' named entity '16 March' named entity 'CRP' named entity 'Hypertension' named entity 'COVID-19' named entity 'risk factor' named entity 'virus entry' named entity 'detection bias' named entity 'COVID-19' named entity 'polymerase chain reaction' named entity 'COVID-19' named entity 'alcohol' named entity 'follow-up' named entity 'glycemic control' named entity 'ethnicity' named entity 'drug trials' named entity 'COVID-19' named entity 'diabetes' named entity 'Clinical studies' named entity 'white British' named entity 'COVID-19' named entity 'central obesity' named entity 'microbes' named entity 'HDL cholesterol' named entity 'COVID-19' named entity 'diabetes' named entity 'A1C' named entity 'Italy' named entity 'pre-clinical' named entity 'RT-PCR' named entity 'confidence interval' named entity 'NICE guidelines' named entity 'risk factors' named entity 'units of alcohol' named entity 'infection' named entity 'blood sample' named entity 'alcohol' named entity 'A1C' named entity 'South Asian' named entity 'glucose homeostasis' named entity 'anti-hypertensive medication' named entity 'COVID-19' named entity 'chemotaxis' named entity 'UK Biobank' named entity 'COVID-19 infection' named entity 'people with diabetes' named entity 'cytotoxic T cells' named entity 'A1C' named entity 'higher end' named entity 'central obesity' named entity 'Declaration of Helsinki' named entity 'regression models' named entity 'people with diabetes' named entity 'intracellular' named entity 'A1C' named entity 'A1C' named entity 'diabetes' named entity '1.04' named entity 'A1C' named entity 'glucose metabolism' named entity 'immune function' named entity 'cardiovascular disease' named entity 'mmHg' named entity 'in-patient care' named entity 'total cholesterol' named entity 'glycaemic control'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software